These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

813 related items for PubMed ID: 19268463

  • 1. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
    Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH.
    Exp Cell Res; 2009 Jul 01; 315(11):1809-18. PubMed ID: 19268463
    [Abstract] [Full Text] [Related]

  • 2. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
    Cheong JW, Chong SY, Kim JY, Eom JI, Jeung HK, Maeng HY, Lee ST, Min YH.
    Clin Cancer Res; 2003 Oct 15; 9(13):5018-27. PubMed ID: 14581377
    [Abstract] [Full Text] [Related]

  • 3. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ, Kim MJ, Kim HB, Kang CD, Kim SH.
    Biochem J; 2009 Apr 28; 420(1):73-81. PubMed ID: 19203346
    [Abstract] [Full Text] [Related]

  • 4. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S.
    Cancer Res; 2003 May 01; 63(9):2118-26. PubMed ID: 12727828
    [Abstract] [Full Text] [Related]

  • 5. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
    Yu C, Krystal G, Dent P, Grant S.
    Clin Cancer Res; 2002 Sep 01; 8(9):2976-84. PubMed ID: 12231544
    [Abstract] [Full Text] [Related]

  • 6. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
    Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH.
    Biochem Pharmacol; 2009 Apr 15; 77(8):1328-36. PubMed ID: 19426671
    [Abstract] [Full Text] [Related]

  • 7. Trail-induced apoptosis in Type I leukemic cells is not enhanced by overexpression of bax.
    Jia L, Patwari Y, Kelsey SM, Newland AC.
    Biochem Biophys Res Commun; 2001 May 25; 283(5):1037-45. PubMed ID: 11355877
    [Abstract] [Full Text] [Related]

  • 8. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
    Wang Z, Sampath J, Fukuda S, Pelus LM.
    Cancer Res; 2005 Sep 15; 65(18):8224-32. PubMed ID: 16166298
    [Abstract] [Full Text] [Related]

  • 9. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 10. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.
    Brieger A, Boehrer S, Schaaf S, Nowak D, Ruthardt M, Kim SZ, Atadja P, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.
    Biochem Pharmacol; 2004 Jul 01; 68(1):85-93. PubMed ID: 15183120
    [Abstract] [Full Text] [Related]

  • 11. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells.
    Mao X, Yu CR, Li WH, Li WX.
    Cell Res; 2008 Aug 01; 18(8):879-88. PubMed ID: 18663379
    [Abstract] [Full Text] [Related]

  • 12. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.
    Cancer Res; 2009 May 01; 69(9):3927-36. PubMed ID: 19366808
    [Abstract] [Full Text] [Related]

  • 13. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA, Greene LM, Greene TF, Campiani G, Butini S, Brindisi M, Lawler M, Meegan MJ, Williams DC, Zisterer DM.
    Biochem Pharmacol; 2009 Feb 01; 77(3):310-21. PubMed ID: 19014913
    [Abstract] [Full Text] [Related]

  • 14. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
    Rahmani M, Reese E, Dai Y, Bauer C, Kramer LB, Huang M, Jove R, Dent P, Grant S.
    Mol Pharmacol; 2005 Apr 01; 67(4):1166-76. PubMed ID: 15625278
    [Abstract] [Full Text] [Related]

  • 15. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
    Choi SY, Kim MJ, Chung HY, Lee SJ, Jang YJ.
    Oncol Rep; 2007 Jan 01; 17(1):175-84. PubMed ID: 17143496
    [Abstract] [Full Text] [Related]

  • 16. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
    Huang HM, Liu JC.
    J Cell Physiol; 2009 Mar 01; 218(3):568-74. PubMed ID: 19006173
    [Abstract] [Full Text] [Related]

  • 17. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
    Greene LM, Kelly L, Onnis V, Campiani G, Lawler M, Williams DC, Zisterer DM.
    J Pharmacol Exp Ther; 2007 Apr 01; 321(1):288-97. PubMed ID: 17202400
    [Abstract] [Full Text] [Related]

  • 18. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 01; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 19. Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation.
    Chandramohan Reddy T, Bharat Reddy D, Aparna A, Arunasree KM, Gupta G, Achari C, Reddy GV, Lakshmipathi V, Subramanyam A, Reddanna P.
    Toxicol In Vitro; 2012 Apr 01; 26(3):396-405. PubMed ID: 22245431
    [Abstract] [Full Text] [Related]

  • 20. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
    Stiewe T, Parssanedjad K, Esche H, Opalka B, Pützer BM.
    Cancer Res; 2000 Jul 15; 60(14):3957-64. PubMed ID: 10919674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.